Home » Regions » Global News » Illumina acquires Australian firm Conexio Genomics

Illumina acquires Australian firm Conexio Genomics

Friday, January 29, 2016

Illumina Inc. is acquiring Conexio Genomics, an Australian firm that specializes in tissue typing used to match patients and donors for bone marrow or cord blood transplants.

Conexio’s system uses a protein found in most cells in the body — human leukocyte antigen or HLA. 

Last year, Illumina introduced its own kit for HLA typing, called the TruSight HLA Sequencing Panel, which is designed to run on the company’s MiSeq benchtop sequencers. Conexio provided the software for that project. As a subsidiary of Illumina, it will continue developing products for more precise organ transplant matching.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!